American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

BIOCRYST PHARMACEUTICALS INC (BCRX)

$7.65 -1.67% NASDAQ: BCRX · 15-min delayed

DURHAM, North Carolina
Public · NASDAQ: BCRX
435 employees

Visit website Follow

$2.4BMarket cap

$25.2MRevenue · FY2017

$263.9MNet income

435Employees

BCRXNASDAQ

1994IPO

About BIOCRYST PHARMACEUTICALS INC

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NASDAQ: BCRX
Employees: 435
IPO date: Mar 3, 1994
Headquarters: 4505 EMPEROR BOULEVARD
DURHAM, North Carolina 27703
Phone: 919-859-1302
Industry: Pharmaceuticals
Website: Visit site

Incorporation record

Incorporated in: DE, United States
Registered office: Wilmington, US
Legal entity ID: 549300Z0INP1Z5NP6J59

Source: GLEIF, the global Legal Entity Identifier registry · checked Jul 26, 2026. A US headquarters does not always mean US incorporation.

Registry IDs

Ticker: BCRX Nasdaq
SEC CIK: 882796
LEI: 549300Z0INP1Z5NP6J59
EIN: 621413174
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Biocryst Pharmaceuticals Inc’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/biocryst-pharmaceuticals-inc/"><img src="https://americancompanies.com/badge/biocryst-pharmaceuticals-inc.svg" alt="Biocryst Pharmaceuticals Inc — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow BIOCRYST PHARMACEUTICALS INC and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2017: $25.2M
Net income: $263.9M
Total assets: $514.2M
Market cap: $2.4B

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: BCRX

$7.65 -1.67%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$6.24 $11.11

52-week range

Market cap: $2.4B
Shares outstanding: 310.3M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Mar 3, 1994

Biocryst Pharmaceuticals Inc (BCRX) Stock Price

Profitable — net income of $263.9M in FY2017.
Trading 31% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review BIOCRYST PHARMACEUTICALS INC.

Write a review

Newsroom

News about BIOCRYST PHARMACEUTICALS INC

BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE GlobeNewswire Inc. · 2026-10-21 · positive 4 Biotech Stocks to Watch as Potential Takeover Targets Zacks Investment Research · 2026-09-18 · positive BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan GlobeNewswire Inc. · 2026-08-25 · positive BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting GlobeNewswire Inc. · 2026-06-12 · positive BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update GlobeNewswire Inc. · 2026-05-06 · positive BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema GlobeNewswire Inc. · 2026-05-04 · positive

News & sentiment via Polygon.io

FAQ

Biocryst Pharmaceuticals Inc: frequently asked questions

Is Biocryst Pharmaceuticals Inc an American company?

Biocryst Pharmaceuticals Inc is a US-based company headquartered in Durham, North Carolina, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Biocryst Pharmaceuticals Inc headquartered?

Biocryst Pharmaceuticals Inc is headquartered in Durham, North Carolina, United States.

Is Biocryst Pharmaceuticals Inc publicly traded?

Yes — Biocryst Pharmaceuticals Inc is a publicly traded company. Its stock trades under the ticker symbol BCRX on the NASDAQ.

What does Biocryst Pharmaceuticals Inc do?

Biocryst Pharmaceuticals Inc is an American Pharmaceuticals company in the Health & Beauty sector.

Explore